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doi:10.1016/j.ejvs.2011.02.012Abstract Background: The goal of treatment for lower extremity peripheral artery disease is
often to improve health status. Factors associated with failure to improve are unknown.
Methods: Health status was assessed with the Peripheral Artery Questionnaire (PAQ) at base-
line and 2 years in 344 patients referred to vascular clinics. Improvement was defined as an
increase of 5 points on the PAQ Summary Score. Multivariable logistic regression identified
patient and treatment characteristics associated with impaired baseline health status, and
predictors of no improvement (<5 points).
Results: Older age, bilateral symptoms, female sex and prior revascularization were associ-
ated with impaired baseline health status. At 2 years 36% reported unimproved health status.
Factors associated with no improvement were older age (Odds Ratio 1.67/decade, CI 1.28,
2.19), better baseline health status (OR 1.40/10-points, CI 1.24, 1.59), beta blocker use (OR
2.53, CI 1.37, 4.68), prior stroke (OR 4.12, CI 1.33, 12.77) and bilateral claudication (OR
1.79, CI 1.07, 2.99).
Summary: Older patients, women, and those with bilateral symptoms or prior revasculariza-
tion have worse health status at vascular referral. Over 1/3 of patients’ health status did
not improve over 2 years; older patients and those with bilateral or milder symptoms, prior
stroke or using beta blockers were less likely to improve.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Saint Luke’s Mid America Heart Institute, 4401 Wornall Road, Kansas City, MO 64111, United States.
2 5798.
(D.M. Safley).
ective Registry and Evaluation of Peripheral Arterial Risks, Events and Distribution) Investigators.
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
356 D.M. Safley et al.Background
specialist for at least 2 years. The current data representsThe hallmark symptom of Peripheral Artery Disease (PAD) is
intermittent claudication (IC). The majority of PAD thera-
pies are directed at treating IC and decreasing cardiovas-
cular risk, as tissue loss or amputation is rare.1,2 Despite the
importance of improving PAD patients’ health status, the
patient factors associated with impaired health status, and
which patient or treatment characteristics may be associ-
ated with a lack of improvements in health status, are
unknown.
The Prospective Registry and Evaluation of Peripheral
Arterial Risks, Events and Distribution (PREPARED-UK)
Registry describes the treatment patterns and outcomes in
stable PAD patients referred to PAD clinics throughout the
United Kingdom.3 PREPARED-UK allows insights into the
outcomes of various treatments among clinically relevant
subsets of PAD patients. Clinical outcomes are reported
separately.4 To capture patients’ health status (symptoms,
function and quality of life), PREPARED-UK used the
disease-specific Peripheral Artery Questionnaire (PAQ) at
the time of initial presentation and in follow-up 2 years
later. We describe changes in health status over time, and
sought to identify those who failed to improve.
Methods
PREPARED-UK is a prospective registry designed to describe
characteristics, treatment patterns and outcomes of
patients with IC presenting for the first time to Vascular
Surgery Units in the UK. As a descriptive study, there is no
protocol-mandated treatment e clinicians at each site
were allowed to practice their usual care. Clinical treat-
ment and outcomes of the entire cohort has been previ-
ously published.4 The UK Multi-Centre Research Ethics
committee approved the study protocol, patient informa-
tion sheet and consent form, and these documents were
then approved by the Local Research Ethics Committees at
participating institutions. Patients provided written
informed consent prior to participation. Patients were also
registered, with their consent, with the Office of National
Statistics (ONS) for long-term follow-up.
Study design
The selection of participating centres and enrollment
criteria have been published previously.3 Initially 25 centres
were recruited to enroll patients, with a goal of 20 consec-
utive referrals enrolled, for a total cohort of 500 patients by
study design. Briefly, potentially eligible patients with IC
were identified through the vascular outpatient surgical
clinics of participating hospitals. Patients were eligible if
they had a clinical history of IC within a walking distance of
<400 m, had an ankle/brachial blood pressure index0.9 at
rest or after exercise, were presenting as a new referral to
a vascular clinic of a participating hospital and were able to
provide written informed consent. A minority of enrollees
had undergone prior vascular bypass, but had been released
from the vascular specialist back to the care of their primary
care physician and had not received care from a vasculara new referral for a de novo episode of symptomatic PAD as
defined above. Patients were excluded if they presented
with critical limb ischemia, including rest pain, necrosis or
ulceration, spinal or venous claudication, or if the claudi-
cation was incidental to presentation with another major
medical condition. To be included in this health status sub-
study, participants needed to survive until the 2-year
assessment andhave completed thebaselinequestionnaires.Health status assessments
Participants were administered health status question-
naires by trained study personnel. These included the PAD-
specific Peripheral Artery Questionnaire (PAQ),5 which was
completed at enrollment, 6 months and 2 years later. This
analysis focuses on the baseline and 2-year scores to
identify clinical factors associated with baseline health
status and predictors of changes in health status over time.
The PAQ is a 20-item, self- or interview-administered
questionnaire that assesses PAD-specific health status. Each
question refers to symptoms attributable to PAD over the
previous 4 weeks.5 Scores are generated for 6 domains,
including Symptoms, Symptom Stability (change in symp-
toms), Physical Limitation, Treatment Satisfaction, Social
Functioning, and Quality of Life. A summary score is
calculated as the average of the Physical Limitation,
Symptoms, Quality of Life, and Social Functioning scores.
Scores range from 0 to 100, where higher scores indicate
lesser degrees of functional limitation, fewer symptoms,
better treatment satisfaction, higher social functioning and
better quality of life. A symptom stability score of 50
represents no change over the preceding 4 weeks, while
scores above or below 50 represent improvement or wors-
ening of symptoms, respectively. This instrument has been
previously described, validated, and shown to be reliable
and responsive in patients before and after peripheral
endovascular revascularization.5
Generic health status was assessed with the EQ5D. This
is a measure of general health from the patient perspec-
tive. The Health Utility Score ranges from 0 to 100, with
higher scores representing better health status.6 This was
administered at baseline, 6 months and 2 years as noted
above. Compliance with recommended medical therapy
was assessed at each of these time points as well. Patients
were grouped into quartiles of initial claudication distances
and improvement was compared to assess whether baseline
walking distances were related to improvement.Definitions
Claudication distance was based on patients’ estimates, as
treadmill testing was not protocol mandated. A current
smoker was defined as smoking within the previous 3
months, and an ex-smoker as a history of smoking but not
within 3 months of enrollment. No assessments of cotinine
levels or carbon monoxide were carried out as part of this
study. Patients were considered to be taking antiplatelet
medications if they reported taking aspirin, clopidogrel,
ticlopidine or dipyridamole.
Figure 1 Patient flow in PREPARED.
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A Steering Committee designed and approved the protocol
and case report forms. The registry was coordinated by the
Clinical Trials and Evaluation Unit of the Royal Brompton
Hospital, London UK and the Northern Vascular Unit,
Freeman Hospital and Newcastle University, Newcastle
upon Tyne UK. Centers were trained on registry procedures
by telephone calls and were instructed to identify consec-
utive eligible patients presenting to the outpatient clinic.
Case report forms were completed and any queries or
missing data points were resolved by direct contact with
the center.
Statistical methods
PAQ change scores were generated by subtracting baseline
scores from 6 month to 2 year scores. These were compared
with a change score of 0 to determine statistical signifi-
cance. Linear regression analysis was performed to identify
clinical factors associated with impaired baseline health
status. After subtracting the baseline scores from the 2 year
assessment, improvement was categorized as a change of
5 points on the PAQ summary score, consistent with
Cohen’s effect size of 25% of the standard deviation of the
baseline PAQ summary score and following a standard
psychometric method for defining meaningful clinical
change.7
Differences between groups are presented as means
with standard deviations, medians with interquartile ranges
or number (%). Continuous variables were compared using
Student’s t-test, and categorical variables with c2. Non-
normally distributed variables were compared with Wil-
coxon nonparametric tests. A multivariable logistic
regression analysis was performed to identify independent
predictors of PAD-specific health status improvement.
Covariates were selected based upon clinical relevance or
the presence of a significant (defined as a p-value <0.10)
bivariate difference between those who did and did not
improve. Model fitness was assessed with Hos-
mereLemeshow test statistic, which indicated no lack of
fit.8 For patients with incomplete 2 year health status data,
multiple imputations were performed using a Markov chain
Monte Carlo method to generate 2 year PAQ summary
scores9 using available baseline health status, clinical and
demographic variables. Comparing the imputed data with
the complete dataset showed the imputed cohort was
younger and more likely to be smokers with worse baseline
health status. There were no significant differences in PAQ
scores at 6 months between those with complete data and
those with imputed data. EQ5D scores were compared at
baseline and follow-up using Student’s t-test. All calcula-
tions were performed using SAS Version 9.0 (SAS Institute,
Cary NC, USA).
Results
A total of 473 patients were enrolled from 23 UK centres
between June 2002 and September 2003. Of these, 75
(15.9%) were enrolled prior to the inclusion of the PAQ in
the study protocol and 39 (9.8%) died before the 2-yearfollow-up, leaving 359 eligible for an assessment of health
status change over the 2 years of observation. Of these, 344
(95.8%) had analyzable baseline PAQ summary scores and
form the cohort for the current analyses. An overview of
the entire patient cohort is shown in Fig. 1. There were 78
patients (22.7%) with partial incomplete follow-up data for
whom generation of the 2-year PAQ summary scores
required the use of multiple imputations. This represents
the proportion of patients without complete data rather
than the percentage of data that was imputed.
Baseline characteristics and clinical outcomes of the
studypopulation of 344 are detailed in Table 1. PAQ subscales
at baseline, 6 months and 2 years are presented in Table 2.
Independent clinical predictors ofworse initial health status,
based upon a multivariable linear regression model, were
older age (3.5 points/decade, 95% CI1.3 to5.6 points),
bilateral symptoms (5.2 points, CI 0.9 to 9.6 points),
female gender (6.2 points, CI 1.6 to 10.9) and prior
peripheral revascularization (13.2 points, CI1.4 to24.9
points).Characteristics associated with lack of
improvement in health status
PAQ summary scores increased to 59.6  23.5 at 2 years for
an average change of 13.1  22 points, a clinically large
improvement. PAQ subscales are presented in Table 2.
Using the criterion of a 5-point increase in PAQ summary
score as the definition of improved health status, 220
patients (64%) improved and 124 (36%) did not. Demo-
graphic and clinical characteristics of those who did and did
not report improvement in PAQ scores are presented in
Table 3, along with univariate comparison of those char-
acteristics between groups. There was no significant
difference in rates of improvement when quartiles of
baseline initial claudication distances were evaluated for
improvement rates (p Z 0.55). Subgroup analysis of PAQ
scores is presented in Table 4.
Variables associated with a lack of improvement in
health status on multivariate analysis are shown in Fig. 2.
Covariates included in the final model were age,medication
Table 1 Baseline Characteristics and Clinical Outcomes.
Overall Baseline Characteristics N Z 344
Age, years 66.5  10.0
Male gender 230 (66.9)
BMI, kg/m2 BSA 26.4  4.4
Caucasian 337 (98.0)
Hypertension 182 (52.9)
Hyperlipidemia 147 (42.7)
Angina 58 (16.9)
Diabetes Mellitus 58 (16.9)
Prior MI 43 (12.5)
Prior CVA 18 (5.2)
Prior CABG 32 (9.3)
Prior PCI 12 (3.5)
Bilateral Claudication 179 (52.0)
Initial Claudication
Distance (metres)a
100 (50, 200)
Absolute Claudication
Distance (metres)a
150 (75, 250)
Ankle Brachial Index e Left 0.7  0.2
Ankle Brachial Index e Right 0.8  0.2
Prior Vascular Bypass 6 (1.7)
Employed 71 (20.6)
Pack-years Smoking History 42  24
Cinical Outcomes
Revascularization 65 (18.9)
NonFatal Myocardial Infarction 7 (2.0)
Stroke 4 (1.2)
Transient Ischemic Attack 3 (0.9)
Coronary Artery Bypass Surgery 7 (2.0)
Congestive Heart Failure 5 (1.5)
All data Number (%) or mean  SD unless otherwise noted.
a Patient Estimates, reported as median (Interquartile
Range).
358 D.M. Safley et al.use, including beta blockers, HMG-CoA reductase inhibi-
tors, antiplatelet medications or diuretics, bilateral clau-
dication symptoms, baseline PAQ summary scores, prior
stroke and myocardial infarction and, gender, history of
treated hypertension or hyperlipidemia, employment
status, and revascularization during the study. Although
there was a trend for more revascularization in the group
with health status improvement (21.8% vs. 13.7%,
p Z 0.065), revascularization was not independently asso-
ciated with health status improvement in multivariableTable 2 Mean PAQ and EQ5D Scores During PREPARED e Overa
PAQ Scale Baseline 6 month Change score
Summary 46.5 55.9 9.3  20.5
QoL 43.4 56.0 12.2  24.3
Symptoms 46.5 56.5 9.9  23.8
Social 56.7 64.9 7.74  26.9
Physical 40.1 47.3 6.4  23.3
Stability 45.7 54.3 8.7  28.2
Satisfaction 82.6 78.6 4.1  24.4
EQ5D 64.1 66.3 1.7  16.3
a p-value Comparing change score vs 0.analyses (Odds Ratio 1.254, 95% confidence interval
0.613e2.564, p Z 0.54).
General health status
The EQ5D scores are presented in Table 2. On average,
those with improved PAQ scores also reported improved
EQ5D scores at 2 years (baseline 62.6 vs. 2 years 66.9,
p Z 0.04). Those with no improvement in PAQ scores
exhibited a trend towards lower EQ5D scores over time
(baseline 66.6 vs. 2 years 62.3, p Z 0.063).
Discussion
The PREPARED-UK Study provides insights into treatment
patterns and outcomes of patients treated at 23 vascular
clinics in the United Kingdom. We found that at the time of
referral, women, older patients, and those with bilateral
claudication or prior revascularization procedures had
worse symptoms. Importantly, over 1/3 of patients failed to
report improved symptoms over the next 2 years. General
health status (EQ5D) measures paralleled the disease-
specific PAQ results, but were less remarkable. Patient
characteristics associated with failure to improve included
bilateral (vs. unilateral) claudication, older age, higher
baseline PAQ summary scores, prior stroke, and beta
blocker use.
These findings are congruent with and extend the existing
literature on the outcomes and treatment patterns of PAD
patients. Additionally the health status of 1/3 of patients
failed to improve, a proportion higher than that reported in
patients undergoing percutaneous endovascular revascular-
ization, in which 1/5 of patients failed to improve.10 Few
differences were identified between those who did and did
not improve following revascularization in that study,
although those without improvement were more likely to
have undergone prior peripheral revascularization or to have
had an unsuccessful procedure. Similar to the current study,
baseline PAQ scores were higher among those with no
improvement. Because all patients underwent revasculari-
zation, multivariable predictors of improvement were not
reported. The MIMIC (Mild to Moderate Intermittent Claudi-
cation) Trials randomized patients to percutaneous revas-
cularization plus optimal medical therapy with structured
exercise, or optimal medical therapy with structured exer-
cise alone. In patients with aorto-iliac as well as femoro-
popliteal disease, those randomized to revascularization hadll (N Z 344).
p-valuea 2 years Change score p-valuea
<0.0001 59.6 13.1  22.1 <0.0001
<0.0001 62.5 17.8  26.7 <0.0001
<0.0001 60.1 12.0  28.3 <0.0001
<0.0001 66.3 6.8  29.5 0.0007
<0.0001 50.6 8.0  27.4 <0.0001
<0.0001 49.6 2.9  23.5 0.048
0.005 79.6 3.0  24.7 0.058
0.09 64.9 0.73  19.4 0.56
Table 3 Comparison of patients reporting improvement vs. no improvement on PAQ Summary Score at 2 years.
Baseline Improved (n Z 220) Not Improved (n Z 124) P-value
Age, years 64.6  10.0 69.8  9.2 < 0.001
Male gender 147 (66.8) 83 (66.9) 0.98
BMI, kg/m2 BSA 26.2  4.2 26.8  4.6 0.26
Caucasian 216 (98.2) 121 (97.6) 0.19
Hypertension 98 (44.5) 84 (67.7) < 0.001
Hyperlipidemia 83 (37.7) 64 (51.6) 0.01
Angina 36 (16.4) 22 (17.7) 0.74
Diabetes Mellitus 33 (15.0) 25 (20.2) 0.22
Prior MI 19 (8.6) 24 (19.4) 0.004
Prior CVA 6 (2.7) 12 (9.7) 0.005
Prior CABG 18 (8.2) 14 (11.3) 0.34
Prior PCI 8 (3.6) 4 (3.2) 1.00
Bilateral Claudication 105 (47.7) 74 (59.7) 0.03
Initial Claudication Distance (meters)a,b 100 (50, 200) 100 (50, 200) 0.06
Absolute Claudication Distance (meters)a,b 150 (75, 250) 200 (100, 300) 0.04
Ankle Brachial Index e Leftb 0.7  0.2 0.7  0.2 0.70
Ankle Brachial Index e Rightb 0.8  0.2 0.7  0.2 0.40
Prior Vascular Bypass 5 (2.3) 1 (0.8) 0.43
Employed 52 (23.6) 19 (15.3) 0.07
Smokers 109 (49.6) 41 (33.1) 0.003
Pack-years Smoking History 43  23 46  24 0.66
Baseline Medication Use
Antiplatelet Medication 144 (65.5) 97 (78.2) 0.01
HMG-CoA Reductase Inhibitor 86 (39.1) 68 (54.8) 0.005
Beta Adrenergic Blocker 29 (13.2) 35 (28.2) < 0.001
Angiotensin Converting Enzyme Inhibitor 46 (20.9) 33 (26.6) 0.23
Diuretic 53 (24.1) 46 (37.1) 0.01
Treatments During Follow-Up
Any new medication 108 (61.4) 58 (49.2) 0.04
Antiplatelet Medication 161 (91.5) 104 (88.1) 0.35
HMG-CoA Reductase Inhibitor 140 (79.5) 92 (78.0) 0.75
Beta Adrenergic Blocker 30 (17.1) 30 (25.6) 0.08
Angiotensin Converting Enzyme Inhibitor 51 (29.1) 41 (34.7) 0.31
Diuretic 58 (33.0) 48 (40.7) 0.18
Smoking Cessation Attemptc 71 (65.1) 26 (63.4) 0.84
Revascularization 0.88
Percutaneous 10 (5.6) 6 (5.0)
Surgical 11 (6.2) 9 (7.6)
All data Number (%) or mean  SD unless otherwise noted.
a Patient Estimates, reported as median (Interquartile Range).
b compared with Wilcoxon nonparametric tests.
c Any method, including medication, nicotine replacement, counseling or hypnosis, reported as % of smokers.
Predictors of Health Status Improvement in PAD Clinics 359better absolute walking distance and ankle/brachial blood
pressure index, but no significant differences were reported
in quality of life.11
By identifying patient characteristics associated with
a higher risk of not improving, we provide a foundation for
future studies to examine how best to proactively identify
and monitor such patients so that their health status
outcomes may be improved. It is unknown whether such
patients would benefit from closer follow-up, more inten-
sive structured exercise programs or medical therapy or
earlier revascularization. However, because symptom relief
is the main treatment goal of PAD along with cardiovascularrisk reduction, close survey for symptomatic response to
treatment is important in identifying those not responsive
to their current treatment.
Bilateral claudication, older age, prior stroke and use of
beta blockers were all significantly associated with a lower
likelihood of health status improvement at 2 years. In
addition, higher baseline PAQ scores were associated with
a lack of improvement. However, no patients had baseline
scores >94, so all patients had the possibility of reporting
a 5 or more point improvement. While most of these risk
factors are not directly modifiable, they do identify groups
that do not enjoy the benefit of treatment to improve
Table 4 Subgroup Comparisons.
Baseline PAQ Sum 2 Year PAQ Sum Change Score p-valuea
Gender
Male 48.4  21.3 61.6  23.3 13.2  23.3 p < 0.001
Female 42.7  19.8 55.7  23.6 13.0  22.7 p < 0.001
p-valueb 0.018 0.028 0.933 N/A
Age
Above Median (67 years) 48.7  20.2 57.2  22.5 8.5  20.2 p < 0.001
Below Median (67 years) 44.3  21.6 62.1  24.3 17.9  23.0 p < 0.001
p-valueb 0.048 0.052 p < 0.001 N/A
Baseline smoking
Smoker 47.1  21.6 64.0  22.2 16.9  22.6 p < 0.001
Non-smoker 46.1  20.5 56.3  24.0 10.2  21.3 p < 0.001
p-valueb 0.673 0.003 P Z 0.005 N/A
a p-value comparing change score vs 0.
b p-value comparing the subgroups.
360 D.M. Safley et al.symptoms of PAD. Use of beta blockers is the sole identified
variable under the direct control of the treating physician,
but is often indicated for PAD patients due to concurrent
coronary artery disease and/or hypertension. Current
recommendations for hypertension control still include
beta blockers as an option in PAD patients12 in part because
prior randomized trials and meta-analyses suggest that
beta blocker use does not worsen symptoms of intermittent
claudication.13,14 It is possible that beta blocker use in this
study is a marker of more advanced cardiovascular disease.
Indeed, prior stroke and bilateral claudication were both
independent predictors of a lack of improvement, and prior
MI was a univariate predictor of no improvement. These are
all markers of more diffuse atherosclerosis, and health
status limitations from PAD are comparable to the limita-
tions from atherosclerotic disease in other vascular beds15
so it is reasonable that more diffuse disease would be
associated with more health status limitations.
The fact that revascularization was not associated with
changes in health status is not unexpected in an open
registry. Conservative medical and structured exerciseFigure 2 Predictors of lactherapy improves walking distances and decreases IC.16e19
However, revascularization produces greater health status
improvements than unstructured exercise programs.20
Percutaneous revascularization appears to offer greater
health status improvement in the short-term21 without
significant difference noted at 2-year follow-up, when
compared to medical therapy.22 Ultimately, the decision
to perform revascularization is carefully tailored to the
individual. However, if a conservative treatment strategy
fails to improve health status, revascularization may need
to be considered as an important therapeutic option. Use
of serial health status measures, such as the PAQ, can help
systematically track the health status of PAD patients and
may help identify those in whom revascularization should
be considered. Subscales of the PAQ are presented in
Table 3, and improved consistently with the summary
score, with the exception of the Treatment Satisfaction
scale. It tended to be higher at initial evaluation, likely
due to patient optimism for improvement as well as to the
new recommendation for specialty care at the time of
referral.k of PAQ improvement.
Predictors of Health Status Improvement in PAD Clinics 361There are several limitations of the PREPARED-UK study
that should be considered when interpreting the results.
First, this was not a randomized comparison, but an
observational report. Thus we can neither determine cause
and effect, nor comment about the potential benefits of
revascularization, as we do not know how those treated
with revascularization may have fared had they not been
treated. Second, the 23 centres included were all in the UK,
and the population was mostly Caucasian and male,
possibly limiting the generalizability of our findings. Third,
there may be unmeasured confounding or other important
mediating factors, such as depression23,24 that were not
collected as part of this study. Data were not available on
all patients, because some died during follow-up or failed
to complete 2-year health status assessments. We did not
include those who died in the same group as those who did
not improve because PAD patients are at high risk for
mortality from a myriad of conditions and we did not know
whether or not their symptoms had improved prior to their
death. Patient estimates were used for initial and absolute
claudication distances, as treadmill testing was not part of
the study protocol. However, there is reasonable correla-
tion with measured distances25 and we do not feel that
their inclusion compromises the results as presented. There
were few patients with prior revascularization procedures,
yet this was a predictor of health status impairment at
baseline. Caution should be used in interpreting results
based on a small sample such as this. Multiple imputation
was used to generate data as needed, and when comparing
the imputed cohort to those with full data there were few
differences between groups. Sensitivity analysis showed
that identical predictors of no improvement were obtained
when all patients with any imputed data were excluded
from the analysis. Although it has been over 5 years since
completion of follow-up in the PREPARED Registry, we feel
that the results remain relevant in the current management
of patients with vascular disease, as the indications for and
goals of treatment remain unchanged.
Conclusions
Among unselected PAD patients referred to vascular clinics,
most patients’ health status improved after 2 years of
treatment. Older PAD patients, females and those with
bilateral symptoms or prior revascularization had more
impaired health status at the time of referral. We also
found that older patients, those with bilateral or milder
symptoms or prior stroke and those taking beta blockers
were more likely to report a lack of health status
improvement after 2 years of treatment in a vascular
specialty clinic. Further research is warranted to assess
whether patients with these characteristics could benefit
from more aggressive follow-up and more intensive treat-
ment if their health status fails to improve.
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